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Abstract The aim of this study was to evaluate the fre-
quency of humoral endocrine organ-specific autoimmunity
in 47,XXYKlinefelter’s syndrome (KS) by investigating the
autoantibody profile specific to type 1 diabetes (T1DM),
Addison’s disease (AD), Hashimoto thyroiditis (HT), and
autoimmune chronic atrophic gastritis (AG). Sixty-one adult
Caucasian 47,XXY KS patients were tested for autoanti-
bodies specific to T1DM (Insulin Abs, GAD Abs, IA-2 Abs,
Znt8 Abs), HT (TPO Abs), AD (21-OH Abs), and AG (APC
Abs). Thirty-five of these patients were not undergoing
testosterone replacement therapy TRT (Group 1) and the
remaining 26 patients started TRT before the beginning of
the study (Group 2). KS autoantibody frequencies were
compared to those found in 122 control men. Six of 61 KS
patients (9.8 %) were positive for at least one endocrine
autoantibody, compared to 6.5 % of controls. Interestingly,
KS endocrine immunoreactivity was directed primarily
against diabetes-specific autoantigens (8.2 %), with a sig-
nificantly higher frequency than in controls (p = 0.016).
Two KS patients (3.3 %) were TPOAb positive, whereas no
patients were positive for AD- and AG-related autoantigens.
The autoantibody endocrine profile of untreated and treated
KS patients was not significantly different. Our findings
demonstrate for the first time that endocrine humoral im-
munoreactivity is not rare in KS patients and that it is more
frequently directed against type 1 diabetes-related au-
toantigens, thus suggesting the importance of screening for
organ-specific autoimmunity in clinical practice. Follow-up
studies are needed to establish if autoantibody-positive KS
patients will develop clinical T1DM.
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Introduction
Klinefelter’s syndrome (KS) is the most frequent sex
chromosomal disorder in men [1], occurring in about 150
per 100,000 men. The genetic background for the KS
phenotype is the presence of one or more extra X chro-
mosome. About 80 % of cases are due to the 47,XXY
karyotype; the remaining 20 % of patients have higher-
grade chromosome aneuploidies, mosaicism, or structurally
abnormal X chromosome [1].
The clinical presentation of KS is primarily character-
ized by gynecomastia, small, firm testes, and hy-
pergonadotropic hypogonadism (high gonadotropin, low
androgens, and high estrogens) [2]. KS has been associated
with thrombosis, varicose veins, type 2 diabetes (T2DM),
bone fractures, epilepsy, and neurological and mental dis-
orders [3] with a significant higher comorbidity rate com-
pared to the general male population. Furthermore, there is
literature evidence of an increase in both humoral and
cellular immunity in male hypogonadism and an increased
frequency of autoimmune diseases in KS patients [4]. This
may be due to sex hormones, that seem to play an im-
portant role as modulators of the onset and/or perpetuation
of autoimmune disease. Steroid hormones have been
shown to be implicated in the immune response, with
estrogens as enhancers of at least humoral immunity and
androgens and progesterone as immune suppressors [5–7].
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Even though KS was first described more than 60 years
ago and various studies have underlined its concomitant
occurrence with autoimmune diseases, our knowledge of
KS-related endocrine autoimmunity is still limited and re-
stricted to a few studies [8, 9]. To date, little information is
available on any endocrine organ-specific autoimmunity in
KS. The aim of our study was therefore to investigate the
frequency of the humoral immune response specific to four
different endocrine autoimmune diseases, namely type 1
diabetes (T1DM), Addison’s disease (AD), Hashimoto thy-
roiditis (HT), and autoimmune chronic atrophic gastritis
(AG), in a cohort of adult Caucasian KS patients with the
classic 47,XXY karyotype. We analyzed serum autoanti-
bodies directed against four well-characterized pancreatic
islet proteins specific for T1DM [insulin, glutamic acid de-
carboxylase (GAD), tyrosine phosphatase 2 (IA-2), and islet
beta-cell zinc cation efflux transporter (ZnT8)] [10, 11];
against the enzyme steroid 21-hydroxylase (21-OH), the
main adrenal autoantigen in AD [12, 13]; against thyroid
peroxidase (anti-TPO Ab) characteristic of HT [14]; and
against gastric parietal cells (APC Ab) specific to AG [15].
Materials and methods
47,XXY KS patients
A total of 61 adult Caucasian KS patients with the classic
47,XXY karyotype were analyzed (median age
35.0 ± 11.4 years; age range 18–63 years). These patients
were recruited from the Center of Rare Diseases, Department
of Experimental Endocrinology, ‘‘Sapienza’’ University of
Rome from 2007 to 2014. The KS diagnosis was based on
clinical features, high levels of follicle-stimulating (FSH) and
luteinizing (LH) hormones and low total testosterone serum
concentrations (T). The diagnosis was confirmed by kary-
otype analysis from cultured peripheral lymphocytes. Serum
FSH,LH,T, estradiol (E2), and sex hormone-binding globulin
(SHBG) concentrations were measured by chemiluminescent
microparticle immunoassay technology (CMIA) (Architect
System, Abbott). The mean serum levels of the hormones
FSH, LH, T, E2, and SHBG were reported in Table 1.
Patients were subdivided and analyzed according to
testosterone replacement therapy (TRT):
Group 1 35 KS patients who had never undergone TRT
(median age 32 years ± SD 10.7; age range 18–56 years);
Group 2 26 KS patients undergoing TRT (median age
37 years ± SD 12.5; age range 19–63 years) (Table 1).
Healthy control subjects
Data from KS patients were compared to those from 122
serum samples collected from healthy men (median age
41 years ± SD 12.1; age range 18–65 years). To establish
a limit of positivity specific for the adult male population a
preliminary study was conducted for each assay, testing
sera from 158 healthy men (median age 42 years ± 12.9;
age range 18–70 years). The limit of positivity of the
methods used in the study was calculated according to the
99th percentile of the values detected in each assay.
All control subjects analyzed had a history of sponta-
neous puberty with gonadotropin levels within the normal
range (Table 1), no clinical evidence of autoimmune dis-
eases and physical parameters within the normal range.
Detection of diabetes-specific autoimmunity
In order to simplify, speed up, and considerably reduce the
costs of screening for diabetes-associated humoral au-
toimmunity, the immune response directed against four
well-characterized pancreatic islet proteins specific to au-
toimmune T1DM (Insulin, GAD, IA-2 and ZnT8) was
measured using a single combined fluid-phase radioim-
munoprecipitation assay based on the detection of the four
autoantibodies in individual assays [novel multi-autoanti-
gen radioimmunoassay (MAA)] [16]. MAA showed 92 %
Table 1 Comparison between KS patients (Group 1 and 2) and control group
Parameters KS patients (n = 61) KS Group 1 (n = 35) KS Group 2 (n = 26) Control Group (n = 122)
Age (years) ± SD range 35 ± 11.4 (18–63) 32 ± 10.7 (18–56) ±37 ± 12.5 (19–63) 41 ± 12.1 (18–65)
Years of follow-up (mean) range 1.5 (0–7) 1.7 (0–7) 1.3 (0–7) 0
TRT mean (years) ± SD 3.0 ± 5.9 0 8 ± 7.4 0
FSH (mIU/ml) ± SD 23.2 ± 17.9 28.5 ± 14.1 15.6 ± 18.9 4.3 ± 1.8
LH (mIU/ml) ± SD 13.2 ± 8.4 15.4 ± 6.7 8.4 ± 8.7 3.2 ± 1.3
T (ng/ml) ± SD 4.8 ± 4.0 5.0 ± 4.9 5.6 ± 2.5 5.9 ± 1.6
E2 (pg/ml) ± SD 31.0 ± 15.9 31.1 ± 16.5 32.2 ± 20.3 29.3 ± 12.6
SHBG (nmol/l) ± SD 45.3 ± 31.8 51.0 ± 33.6 31.3 ± 13.4 34.2 ± 14.1
TRT testosterone replacement therapy, FSH follicle-stimulating hormone, LH luteinizing hormone T testosterone, SHBG sex hormone-binding
globulin, E2 estradiol
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sensitivity and 99 % specificity in the Diabetes Autoanti-
body Standardization Program (DASP) held in 2010. Only
MAA-positive sera were subsequently tested in single as-
says to determine individual diabetes-specific humoral
immunoreactivities.
Diabetes-specific single autoantibody measurements
Insulin autoantibodies Insulin antibodies were measured
using a competitive fluid-phase radioimmunoassay (RIA)
[17], with minor modifications. 125I radiolabelled insulin
was purchased from Adaltis Italia (RADIM SpA, Italy).
This assay achieved 46 % sensitivity and 100 % specificity
for insulin antibody detection at the Islet Autoantibody
Standardization Workshop (IASP) held in 2012.
GAD autoantibodies GAD antibodies were measured by
a previously described RIA fluid-phase method [18] using a
human recombinant full-length GAD65 cDNA provided by
Dr A˚. Lernmark (Lund University, Malmo¨, Sweden). The
GADA assay achieved 80 % sensitivity and 98 % speci-
ficity at the Fourth DASP held in 2007 [19].
IA-2 autoantibodies IA-2 antibodies were detected by a
RIA fluid-phase method [20] using a human recombinant
IA-2 (a.a.605–979) cDNA provided by Dr E. Bonifacio
(University of Dresden, Dresden, Germany). The IA-2A
autoantibody assay achieved 72 % sensitivity and 99 %
specificity at the Fourth DASP [19].
ZnT8 autoantibodies ZnT8 antibodies were detected by a
RIA fluid-phase method using human ZnT8 probe (pJH4,1)
provided by John Hutton (University of Colorado, Denver,
USA) [21]. The ZnT8A assay achieved 58 % sensitivity
and 93 % specificity at the standardization program for
determination of 21-OH Abs held in 2011 [22].
Detection of adrenal-specific autoimmunity
Autoantibodies against the enzyme steroid 21-hydroxylase
(21-OH Abs) were tested by RIA fluid-phase assay using a
human recombinant human 21-OH provided by Alberto
Falorni (University of Perugia, Perugia, Italy). The
21-OHAb assay achieved 94 % sensitivity and 100 %
specificity at the first international serum exchange for the
determination of 21-hydroxylase autoantibodies [23].
Detection of thyroid-specific autoimmunity
Thyroid peroxidase autoantibodies (anti-TPO Abs) [24]
were measured using Architect chemiluminescent mi-
croparticle immunoassays (CMIA) (Architect System,
Abbott Diagnostic Division, United States).
Detection of gastric-specific autoimmunity
Parietal cell autoantibodies (APC Abs) specific for au-
toimmune chronic AG [25] were measured using a com-
mercially available ELISA kit (Axa Diagnostics, Italy).
Statistical analysis
SAS 9.2 software was used for statistical analysis. Data
were expressed as frequencies or as mean ± standard de-
viation or median values. Frequency differences were
calculated by Fisher’s exact test. A p value \0.05 was
considered significant.
Results
Endocrine organ-specific humoral autoimmunity
in 47,XXY KS patients and in healthy men
The overall frequency of organ-specific autoimmunity in
our cohort of 47,XXY KS patients and in our male controls
was 9.8 % (95 % CI 2.3–17.3) and 6.5 % (95 % CI
2.2–10.8), respectively. Six of 61 KS patients and 8 of 122
controls were positive for at least one of the organ-specific
autoantibodies investigated. The distribution of the au-
toantibody frequencies in our KS patients and control
group is reported in Fig. 1.
Diabetes-specific autoimmunity
Five of the 61 47,XXY KS patient serum samples analyzed
(8.2, 95 % CI 1.3–15.1) were multi-autoantigen (MAA)
positive, with a significantly higher frequency than in the
control group (0.8 %, 1/122, 95 % CI -0.8 to 2.4)
(p = 0.0163).
Subsequently, the MAA-positive sera were tested in
single assays to determine individual diabetes-specific hu-
moral immunoreactivities. Three KS cases and one control
were positive for just one diabetes-specific autoantibody
(GAD Abs, IA-2 Abs or ZnT8 Abs), while the other 2 KS
patients were each positive for two autoantibodies (GAD/
IA-2 Abs and GAD/Insulin Abs, respectively) (Table 2).
Adrenal-specific autoimmunity
None of the 61 KS patients or 122 controls investigated
was autoantibody-positive for 21-OH Abs.
Thyroid-specific autoimmunity
The anti-TPO autoantibody frequency in KS patients and
controls was 3.3 % (2/61, 95 % CI -1.2 to 7.8) and 6.5 %
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(8/122, 95 % CI 2.2–10.8), respectively. In one case, the
thyroid-specific autoimmune marker was combined with
diabetes-specific immunoreactivity (Table 2).
Gastric-specific autoimmunity
None of the 61 KS patients was positive for gastric parietal
cell autoantibodies. One of the 122 controls (0.8 %, 1/122,
95 %CI-0.8 to 2.4) showed gastric-specific autoimmunity.
Endocrine organ-specific humoral autoimmunity
in 47,XXY KS patients subdivided by TRT
The autoantibody frequency distribution in KS patients
with no history of previous TRT (Group 1), in KS patients
undergoing TRT (Group 2), and in controls is reported in
Fig. 2.
Serum samples from 4 (11.4, 95 % CI 0.9–21.9) of the
35 TRT-naı¨ve KS patients were positive for at least one of
the organ-specific autoantibodies investigated. This fre-
quency was not significantly higher than the 7.7 % (2/26,
95 % CI -2.5 to 17.9) found in samples from the 26 KS
patients undergoing TRT.
Comparison of the distribution of organ-specific au-
toantibody frequency in the two KS groups revealed that
diabetes-specific autoimmunity was 8.6 % (3/35, 95 % CI
-0.7 to 17.9) in TRT-naı¨ve and 7.7 % (2/26, 95 % CI -2.5
to 17.9) in TRT-treated KS patients. Furthermore, it was
significantly higher in TRT-naive patients than in controls
(3/35 vs. 1/122, p = 0.034). The difference between Group
1 and 2 KS patients was not significant, as well as between
Group 2 KS patients and controls. TPO Abs positivity was
found only in Group 1 (5.7 %, 2/35, 95 % CI -1.7 to 13.1)
with a frequency similar to that observed in the control
Fig. 1 Frequency of endocrine autoantibody specificities in the 61
47,XXY KS patients and 122 healthy men investigated. Diabetes-
specific Abs: glutamic acid decarboxylase (GAD Abs), insulin
(Insulin Abs), tyrosine phosphatase (IA-2 Abs), and islet beta-cell
zinc cation efflux transporter (ZnT8 Abs) autoantibodies; Adrenal
Abs: 21-hydroxylase antibodies; Thyroid Abs: thyroid peroxidase
antibodies (TPO Abs); Gastric Abs: autoantibodies to the gastric
parietal cell (APC Abs)
Table 2 Immunoreactivity patterns in 47,XXY KS autoantibody-positive patients with no history of previous hormone replacement therapy and
in patients undergoing therapy
47,XXX
patients
Years TRT TRT
(years)
MAA 21-OH
Abs
TPO
Abs
APC
Abs
Auto immune disease
development
Follow-up
(years)
Therapy
1 18 - 0 - - ? - HT 2 Levotiroxina
2 28 ? 5 ? (AAI abd
GAD Abs)
- - - - 0 –
3 31 ? 11 ? (IA-2 Abs) - - - - 0 –
4 34 - 0 ? (Znt8 Abs) - - - - 0 –
5 39 - 0 ? (GAD and IA-
2 Abs)
- ? - T1DM 4 Insulin
6 43 - 0 ? (GAD Abs) - - - - 2 –
MAA multi-autoantigen radioimmunoassay, GAD Abs glutamic acid decarboxylase, IA-2 Abs tyrosine phosphatase autoantibodies, ZnT8 Abs islet
beta-cell zinc cation efflux transporter autoantibodies, 21-OH Abs 21-hydroxylase antibodies, TPO Abs thyroid peroxidase antibodies, APC Abs
autoantibodies against the gastric parietal cells
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group (6.5 %, 8/122). Thyroid-specific immunoreactivity
of KS patients undergoing TRT was not significantly lower
than in the control group (0/26 vs. 8/122). No KS patient or
control was positive for 21-OH Abs or APC Abs and only
one control was found positive for gastric-specific
autoimmunity.
Autoantibody-positive 47,XXY KS patients
The clinical and autoimmune patterns of the autoantibody-
positive KS patients (9.8 %, 6/61) are presented in Table 2.
Four of these six patients had no history of TRT, while two
were undergoing TRT at the time of blood sample collec-
tion (mean therapy duration: 8 years, range 5–11 years).
The serum sample from one KS patient was positive for
different organ-specific immunoreactivities, thus placing
him at risk of developing polyendocrinopathy. In this case,
diabetes-specific autoimmunity (GAD and IA-2) was as-
sociated with a positivity for TPO Abs. In the other five
patients, only single organ-specific immunoreactivities
were detected, with one serum sample positive for anti-
TPO Abs and the other four positive for diabetes-specific
Abs (GAD Abs, Znt8 Abs, GAD/Insulin Abs, and IA-2,
respectively).
One autoantibody-positive patient from Group 1 (1/4)
started TRT during the study. Comparison of endocrine
organ-specific humoral immunoreactivity before and after
the beginning of TRT revealed a decrease in humoral re-
sponse (data not shown). The two immunoreactive KS
patients in Group 2 began TRT before being enrolled in the
study, thus preventing comparison of autoantibody titers
before and after the beginning of TRT.
Discussion
This study investigated for the first time the endocrine
autoantibody profile of four different organ-specific au-
toimmune diseases (T1DM, AD, HT, and autoimmune
chronic AG) in the same cohort of 61 adult 47,XXY
Klinefelter patients. It is well known that autoimmune
diseases generally show sexual dimorphism, predominantly
affecting females [5]. For this reason, before analyzing our
patients for the presence of the various endocrine autoan-
tibodies, and with the aim of avoiding gender bias in our
results, we decided to calculate the limit of positivity for
each assay by using an adult cohort of 158 male subjects.
For the same purpose, we compared the endocrine au-
toimmunity profile of our KS patients against that found in
double the number of healthy men.
Altogether, we found that 9.8 % of 47,XXY KS patients
showed organ-specific endocrine humoral immunoreac-
tivity, with a higher frequency than in the control group
(6.5 %).
Literature evidence shows that diabetes mellitus is fre-
quently associated with KS [26, 27]. However, these
studies rarely distinguished between type 1 and type 2
diabetes. Clinical information suggests that most patients
had T2DM [3]. In 2012, a study analyzing coexisting
conditions in T1DM patients reported that 1.9 % of T1DM
Fig. 2 Frequency of endocrine autoantibody specificities in 47,XXY
KS patients with no history of previous hormone replacement therapy
(Group 1), in patients undergoing therapy (Group 2) and in healthy
men. Diabetes-Specific Abs: glutamic acid decarboxylase (GAD
Abs), insulin (Insulin Abs), tyrosine phosphatase (IA-2 Abs), and islet
beta-cell zinc cation efflux transporter (ZnT8 Abs) autoantibodies;
Adrenal Abs: 21-hydroxylase antibodies; Thyroid Abs: thyroid
peroxidase antibodies (TPO Abs); Gastric Abs: autoantibodies to
the gastric parietal cell (APC Abs)
Endocrine
123
patients had KS [28]. It is now well known that the pres-
ence of diabetes-specific autoimmunity may help to dif-
ferentiate type 1 from T2DM [29]. There is only sporadic
information, coming essentially from case reports, on the
frequency of diabetes-specific immunoreactivity in KS
patients [30, 31]. This is essentially due to the low number
of autoantibodies (in particular diabetes-specific) identified
at the time of these studies and possibly also to the low
sensitivity and specificity of the available assays. In this
study, we evaluated diabetes-specific humoral immunore-
activities by using an innovative assay that achieved high
sensitivity and specificity at the 2010 Diabetes Antibody
Standardization Program [16]. We found that 8.2 % of
47,XXY KS patients were positive for at least one of the
four diabetes-specific autoantibodies investigated, with no
significant difference between KS patients receiving or not
receiving TRT. Interestingly, irrespective of TRT, the
diabetes-specific autoantibody frequency in KS was sig-
nificantly higher than in the healthy controls used in our
study and was comparable to that described in literature for
first degree relatives of T1DM patients [32, 33]. As re-
ported in the literature, the presence of two or more of
these autoantibodies confers a[50 % risk of developing
T1DM within 5 years in relatives of patients with T1DM
[34, 35], and GAD65 and IA-2 antibodies are the strongest
predictors of T1DM [36].
In our cohort of KS immunoreactive patients, two serum
samples showed double positivity for diabetes-specific
immunoreactivities, with GAD and IA-2 autoantibodies
more frequent than the other diabetes-specific autoanti-
bodies. It is worth noting that the GAD- and IA-2 au-
toantibody-positive KS patient in this cohort went on to
develop clinical T1DM and is currently under insulin
treatment. The other case, namely the GAD- and Insulin-
Abs positive KS patient, shows no clinical or biochemical
evidence of autoimmune diabetes to date.
In line with the already known higher susceptibility of
T1DM patients to other autoimmune disorders [37], the KS
patient with T1DM was also positive for anti-TPO au-
toantibodies, the marker of Hashimoto’s thyroiditis. Thy-
roid autoimmunity was present in 3.3 % of KS patients,
with no significant differences compared to the control
group. The TPO antibody frequency in TRT-naı¨ve patients
(5.7 %) was similar to that found in previous studies
(5.4 %) [8, 9] and was higher in these patients than in those
undergoing TRT.
To our knowledge, this is the first study investigating
gastric parietal and adrenal humoral autoimmunity in KS.
These endocrine immunoreactivities were not found in our
cohort of 47,XXY KS patients.
In conclusion, our results provide additional weight to the
already known concept of enhanced immune response in KS
patients and, for the first time, we report a comprehensive
pattern of endocrine organ-specific autoimmunity in adult
Caucasian 47,XXY KS patients. Diabetes-specific humoral
immunoreactivity is the most frequent endocrine organ-
specific autoimmunity in these patients and is significantly
increased in comparison with healthy men.
Autoantibody formation precedes the possible develop-
ment and progression of most autoimmune disorders. Over
the course of our study, these autoantibodies showed
clinical significance; the GAD/IA-2 Ab positive patient
was diagnosed with T1DM and the TPO Ab positive pa-
tient with thyroiditis. Both these patients were asymp-
tomatic at the time of autoantibody detection. They are
now being treated respectively with insulin and with
levotiroxina (Table 2). The other four KS immunoreactive
KS patients were all asymptomatic.
Detection of serum autoantibodies may therefore help in
identifying KS patients at risk of developing organ-specific
autoimmune diseases (thus preventing morbidity related to
unrecognized diseases) and in monitoring the preclinical
and clinical phases of the disease. We suggest that
screening for diabetes and thyroid-specific autoimmunity
in every KS patient and follow-up of the immune response
should be considered in KS clinical practice.
Testosterone replacement therapy autoantibody fre-
quencies in TRT-naı¨ve KS patients were comparable to
those in patients undergoing TRT. Furthermore, one au-
toantibody-positive KS patient with low testosterone levels
underwent TRT during the study, showing decreasing im-
munoreactivity (data not shown). As hypothesized by Ko-
car et al. [38], this reduction might be related at least in part
to the immunosuppressive effects of testosterone. Howev-
er, it is not possible to affirm that TRT does not influence
autoimmunity in KS patients, because it is unclear if it
might induce large biochemical differences in our treated
KS group. Additional longitudinal studies are needed to
understand the potential effect of TRT and its duration on
autoantibody production in KS. Nevertheless, it is impor-
tant to underline that not only endocrine but also several
other intrinsic and extrinsic etiologic factors such as ge-
netic predisposition and environmental factors may con-
tribute to autoimmune disease progression and
pathogenesis. Moreover, the long term consequences of
hypergonadotropic hypogonadism in KS patients are dif-
ficult to separate from the gene-dose effects of the X
chromosome aneuploidy. In addition to the existing lit-
erature reports [4, 39, 40], further studies on KS patients
with higher X chromosome aneuploidies are needed to
clarify the relationship between the gene-dose effect and
androgen levels in the development and maintenance of
endocrine organ-specific humoral autoimmunity.
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